Generated by AI
Biomea Fusion Inc. is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for diabetes, obesity, and other metabolic diseases. Its current pipeline centers on icovamenib, a menin inhibitor being studied across multiple diabetes programs, and BMF-650, an oral GLP-1 receptor agonist in development for obesity. The company’s work is built around covalent chemistry and precision drug design, with an emphasis on therapies intended to address biologically defined patient groups. Biomea Fusion Inc. also explores applications in genetically defined cancers through its broader small-molecule research platform. Headquartered in San Carlos, California, Biomea Fusion Inc. plays a role in the biopharmaceutical market as a developer of investigational treatments aimed at challenging endocrine and metabolic conditions.
Website1599 Industrial Road
San Carlos, CA, 94070
United States
The latest articles about BMEA.
Biomea Fusion reports Phase 1 BMF-650 results, with weight reduction and safety data from its oral GLP-1 drug trial.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 11's posts. Generated by AI.
2026-10-14. The following slide deck was published by Biomea Fusion, Inc.
Summary of Mar 29's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about BMEA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.